Evidence map›Paper›PMID 34786710›Full record

ArticleBiotechnology and bioengineering2022

An integrated yeast-based process for cis,cis-muconic acid production.

Guokun Wang, Aline Tavares, Simone Schmitz, Lucas França, Hugo Almeida, João Cavalheiro, Ana Carolas, Süleyman Øzmerih, Lars M Blank, Bruno S Ferreira and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Efficient Synthesis ofMolecules (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Guokun WangThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-6151-3980
Aline TavaresBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
Simone SchmitzThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
Lucas FrançaBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
Hugo AlmeidaBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
João CavalheiroBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
Ana CarolasBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
Süleyman ØzmerihThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
Lars M BlankInstitute of Applied Microbiology-iAMB, Aachen Biology and Biotechnology-ABBt, RWTH Aachen University, Aachen, Germany.
Bruno S FerreiraBiotrend - Inovação e Engenharia em Biotecnologia SA, Cantanhede, Portugal.
Irina BorodinaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-8452-1393
Biotrend (Portugal) · PTNovo Nordisk Foundation · DKChinese Academy of Sciences · CNRWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cis,cis-muconic acid (CCM) is a promising polymer building block. CCM can be made by whole-cell bioconversion of lignin hydrolysates or de novo biosynthesis from sugar feedstocks using engineered microorganisms. At present, however, there is no established process for large-scale CCM production. In this study, we developed an integrated process for manufacturing CCM from glucose by yeast fermentation. We systematically engineered the CCM-producing Saccharomyces cerevisiae strain by rewiring the shikimate pathway flux and enhancing phosphoenolpyruvate supply. The engineered strain ST10209 accumulated less biomass but produced 1.4 g/L CCM (70 mg CCM per g glucose) in microplate assay, 71% more than the previously engineered strain ST8943. The strain ST10209 produced 22.5 g/L CCM in a 2 L fermenter with a productivity of 0.19 g/L/h, compared to 0.14 g/L/h achieved by ST8943 in our previous report under the same fermentation conditions. The fermentation process was demonstrated at pilot scale in 10 and 50 L steel tanks. In 10 L fermenter, ST10209 produced 20.8 g/L CCM with a CCM yield of 0.1 g/g glucose and a productivity of 0.21 g/L/h, representing the highest to-date CCM yield and productivity. We developed a CCM recovery and purification process by treating the fermentation broth with activated carbon at low pH and low temperature, achieving an overall CCM recovery yield of 66.3% and 95.4% purity. In summary, we report an integrated CCM production process employing engineered S. cerevisiae yeast.

Indexed as

Saccharomyces cerevisiaeFermentationGlucoseMetabolic EngineeringSorbic AcidGlucosemuconic acidSorbic Acidfermentationmetabolic engineeringpurificationrecoverySaccharomyces cerevisiae

Identifiers

PMID34786710
PMCPMC9299173
OpenAlexW3212121023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.